TG Therapeutics Investigational Trial Site

Washington D.C., District of Columbia 20010

2 studies enrolling now · 5 studies all time

What they study most

Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Multiple Sclerosis, Non Follicular Indolent Non-Hodgkin Lymphoma, Relapsing Multiple Sclerosis, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia

Studies at this site

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — Recruiting now
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — Recruiting now
• Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy — Stopped early
• Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma — Completed
• Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma — Stopped early